Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.64 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090606 | 0.87 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL3077043 | 0.82 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5269011 | 0.80 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL23870500 | 0.79 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL2684425 | 0.78 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL13591433 | 0.75 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5274463 | 0.73 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5270084 | 0.73 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5269006 | 0.71 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL13591441 | 0.71 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109612-B1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| EP-2109612-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | AstraZeneca AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008093075-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AA1 1/4885HSP90AB1 2/4885ROCK2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.